Homma, Shunichi
Messé, Steven R.
Rundek, Tatjana
Sun, Yee-Ping
Franke, Jennifer
Davidson, Karina
Sievert, Horst
Sacco, Ralph L.
Di Tullio, Marco R.
Article History
First Online: 21 January 2016
Competing interests
: S.H. has served on the data safety and monitoring board for the RESPECT trial with St. Jude Medical and as an ad hoc consultant with Daiichi Sankyo and Bristol-Meyers Squibb Pfizer. S.R.M. is the local principal investigator for the Gore Helex Reduce trial, for which he has received salary support (modest, that is, <$5,000 per year). He has also received travel support from the American Academy of Neurology (AAN) to attend the Guideline Development Subcommittee meetings. H.S. has received study honoraria, travel expenses and consulting fees (<€25,000) from Abbott, Aptus Endosystems, Atrium, Biosense Webster, Boston Scientific, Carag, Cardiac Dimensions, CardioKinetix, CardioMEMS, Cardiox, Celonova, CGuard, Coherex Medical, Comed B.V., Contego Medical, Covidien, CSI, CVRx, ev3, FlowCardia, Gardia Medical, Gore, GTIMD Catheter Solutions, Guided Delivery Systems, Hemoteq, InSeal Medical, InspireMD, Kona Medical, Lumen Biomedical, Lifetech Scientific, Lutonix, Maya Medical, Medtronic, Occlutech, pfm Medical, Record, ResMed, SentreHeart, Spectranetics, Svelte Medical Systems, Tendyne, TriReme Medical, Trivascular, Valtech, Vascular Dynamics, Venus Medical, Veryan Medical and Vessix Vascular. He also owns stock options (<€25,000) from Cardiokinetix, Access Closure, Coherex Medical and SMT Medical. R.L.S. was a past consultant to Boehringer Ingelheim for the design and implementation of a secondary stroke prevention trial with dabigatran versus aspirin. The other authors have no relevant financial relationships with industry to disclose.